Haemonetics (HAE) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Haemonetics (HAE) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 89.28% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -30.10% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 121.14% |
| 10 | Haemonetics | 3.78 Bn | 3.54 Bn | 198.21 Mn | -134.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -134.75% |
| Dec 27, 2025 | 19.25% |
| Sep 27, 2025 | 14.35% |
| Jun 28, 2025 | -11.22% |
| Mar 29, 2025 | 184.12% |
| Dec 28, 2024 | 20.09% |
| Sep 28, 2024 | 35.69% |
| Jun 29, 2024 | -6.61% |
| Mar 30, 2024 | -30.65% |
| Dec 30, 2023 | -5.17% |
| Sep 30, 2023 | -24.81% |
| Jul 1, 2023 | 106.72% |
| Apr 1, 2023 | 202.06% |
| Dec 31, 2022 | 42.07% |
| Oct 1, 2022 | 123.71% |
| Jul 2, 2022 | 546.27% |
| Apr 2, 2022 | 188.23% |
| Jan 1, 2022 | -27.27% |
| Oct 2, 2021 | -69.19% |
| Jul 3, 2021 | -142.31% |